F-4185 Foretinib, Free Base, >99%

Synonyms : [Exel-2880] [GSK-1363089] [GSK089] [XL-880]

  • Size
  • US $
  • £
  • ¥
  • 5 mg
  • 38
  • 33
  • 28
  • 4,300
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 49
  • 43
  • 36
  • 5,600
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 79
  • 69
  • 59
  • 9,000
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 127
  • 112
  • 95
  • 14,400
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
  • M.W. 632.65
  • C34H34F2N4O6
  • [849217-64-7]

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-10 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • Foretinib, also known as EXEL-2880, XL880, and GSK1363089, is a small-molecule inhibitor of the hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) receptor tyrosine kinase families.
  • Foretinib inhibited receptor tyrosine kinases (RTKs) in vitro with IC50 values of 0.4 nM for Met and 3 nM for Ron. It inhibited cellular Met with IC50 values of 23 nM in PC-3 prostate cells and 21 nM in murine B16F10 melanoma cells. It also reduced tumor cell migration, invasion, and endothelial tubule formation. Foretinib had cytotoxic activities against a broad panel of cell lines. It also blocked lung metastasis after the implantation of B16F10 solid tumors in mice. Qian, F., et al. "Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases." Cancer Res. 69: 8009-8016 (2009).
  • MET-amplified tumor lines with HER1 or HER2 amplification are more sensitive to the combination of foretinib with lapatinib or erlotinib. MET-overexpressing tumor cell lines with HER1 or HER2 amplification are less sensitive to lapatinib or erlotinib in the presence of HGF. Foretinib can reverse the effect of HGF on lapatinib or erlotinib sensitivity in these cells. Liu, L., et al. "Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells." Mol. Cancer Ther. 10: 518-530 (2011).
  • Foretinib inhibits tumorigenesis and blocks invasive tumor growth in different models of ovarian cancer by affecting several critical tumor functions including inducing anoikis (anchorage-dependent programmed cell death) and inhibiting (1) c-Met activation and downstream signaling, (2) ovarian cancer cell adhesion, (3) migration and invasion, and (4) proliferation. Zillhardt, M., et al. "Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis." Clin. Cancer Res. 17: 4042-4051 (2011)
  • Foretinib potently block multiple RTKs, including VEGF receptor and the receptor of HGF c-Met. Inhibition of c-Met and functionally related kinases intensifies the effects of VEGF receptor blockade, which leads to regression of tumor vasculature. You, W.K., et al. "VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer." Cancer Res. 71: 4758-4768 (2011).
  • Foretinib caused mitotic catastrophe in chronic myelogenous leukemia cells and other cell lines by JNK-dependent inhibition of Plk1 expression and induced apoptosis via a caspase 2-mediated mechanism. Dufies, M., et al. "Mechanism of action of the multikinase inhibitor Foretinib." Cell Cycle 10: 4138-4148 (2011).
  • Foretinib had cytotoxic effects against gastric cancer cells harboring MET and FGFR2 amplification. It exerted its cytotoxic effects by blocking inter-RTK signaling networks with MET or FGFR2 at their center. Kataoka, Y., et al. "Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks." Invest. New Drugs 30: 1352-1360 (2012).
  • Foretinib was shown to have significant antitumor activities in patient-derived hepatocellular carcinoma xenograft models. Huynh, H., et al. "Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma." Angiogenesis 15: 59-70 (2012).
  • Another CAS number previously assigned to foretinib free base , namely 937176-80-2, has been deleted by CAS and is no longer in use.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • his product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.